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Abstract
Background: Metabolic flux profiling based on the analysis of distribution of stable isotope tracer in metabolites is
an important method widely used in cancer research to understand the regulation of cell metabolism and
elaborate new therapeutic strategies. Recently, we developed software Isodyn, which extends the methodology of
kinetic modeling to the analysis of isotopic isomer distribution for the evaluation of cellular metabolic flux profile
under relevant conditions. This tool can be applied to reveal the metabolic effect of proapoptotic drug edelfosine
in leukemia Jurkat cell line, uncovering the mechanisms of induction of apoptosis in cancer cells.
Results: The study of
13C distribution of Jukat cells exposed to low edelfosine concentration, which induces
apoptosis in ≤5% of cells, revealed metabolic changes previous to the development of apoptotic program.
Specifically, it was found that low dose of edelfosine stimulates the TCA cycle. These metabolic perturbations were
coupled with an increase of nucleic acid synthesis de novo, which indicates acceleration of biosynthetic and
reparative processes. The further increase of the TCA cycle fluxes, when higher doses of drug applied, eventually
enhance reactive oxygen species (ROS) production and trigger apoptotic program.
Conclusion: The application of Isodyn to the analysis of mechanism of edelfosine-induced apoptosis revealed
primary drug-induced metabolic changes, which are important for the subsequent initiation of apoptotic program.
Initiation of such metabolic changes could be exploited in anticancer therapy.
Background
The characterization of metabolic flux profile in living
cells is an important issue in understanding the regula-
tion of normal metabolism and the development of dis-
ease processes. Such characterization is then necessary
for the development of novel therapeutic strategies.
Stable isotope tracing using [1,2-
13C2]-glucose as a
source of carbon, has been described as a very powerful
tool for metabolic flux profiling [1-6]. The specific pat-
tern of various
13C isotopic isomers (isotopomers) frac-
tions measured using mass spectrometry or nuclear
magnetic resonance techniques characterized the distri-
bution of metabolic fluxes in the cells under the studied
conditions. To evaluate the flux distribution from mea-
sured isotopomer distribution a special software tool is
necessary.
Classical
13C metabolic flux analysis (MFA) evaluated
steady state metabolic fluxes based on isotopomer frac-
tions measured under the conditions of isotopic steady
state [7]. For non-stationary metabolic flux analysis we
developed a tool called “Isodyn” (from “isotopomer
dynamics”)[ 8 - 1 0 ]t h a ts i m u l a t e s
13C redistribution in
metabolites by automatically constructing and solving
large systems of differential equations for isotopomers.
Although intracellular metabolites could reach isotopic
steady state in a range of minutes, the existence of intra-
cellular stores essentially delays the time necessary for
establishing isotopic steady state. Such stores as glyco-
gen, aminoacids and lipids, which intensively exchange
with intermediates of central carbohydrate metabolism,
could prolong the pre-steady state phase for all isotopo-
mers. Of course, there is always a possibility of
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13C-MFA for the “fast” intermediates of central metabo-
lism considering that they are in quasi-steady state.
However, the simulation of such “slow” variables pro-
vides additional information for the determination of
the characteristics of the system.
Moreover, there is another reason for using non-sta-
tionary analysis based on a kinetic model of considered
pathways: it allows, when experimental data is enough, a
more profound analysis of kinetic characteristics and
regulation in the pathway. Such advantages stimulated
the development of other bioinformatic tools for non-
stationary flux analysis [11]. Here, an application of
Isodyn for revealing the characteristics of cancer cell
metabolism and their change induced by a proapoptotic
agent edelfosine is described.
Apoptosis is a programmed cell death and the evasion
of apoptotic programm is one of the most fundamental
characteristics of cancer cells [12]. However, trans-
formed cells still possess the components of apoptotic
mechanism, and it could be induced by various agents.
The strategy of selectively killing tumor cells by indu-
cing apoptosis could be used for cancer therapy [13,14],
and the presented analysis provides information for the
development of such strategy.
Apoptotic process is a complex sequence of signaling
events and metabolic changes. The cascade of signaling
events resulting in cell death is well studied. However,
the signals to apoptosis could be seen as a result of
severe distortions in metabolism. In this way, the meta-
bolic changes could be primary events that activate or
inhibit apoptotic process. For example, the stimulation
of mitochondrial metabolism related to reactive oxygen
species (ROS) production [15-17] or the inhibition of
glycolisis [18] has been linked with activation of apopto-
tic cascade. Our objective was to understand whether
relevant metabolic changes precede the development of
apoptosis, or they just follow the progression of the
apoptotic signaling program. To reveal the early meta-
bolic changes, the metabolic effects of very low doses of
edelfosine, which induce apoptosis in less than 5% of
cellular population, were studied.
Synthetic antitumour ether phospholipid edelfosine
(1-O-octadecyl-2-O-methylrac-glycero-3-phosphocho-
line, ET-18-OCH3) selectively induces apoptosis in can-
cer cells [19-25]. The cell-killing mechanism of
edelfosine is mediated by signalling events such as
blocking some protein kinases [26] or activation of spe-
cific apoptotic receptors [21 ] .A l s oe d e l f o s i n ei n d u c e s
the increase in mitochondrial reactive oxygen species
(ROS) production [20,27], which could be a conse-
quence of certain metabolic distortions. If metabolic
changes are primary with respect to the development of
apoptotic program, it could be expected that essential
changes in cell metabolism could take place at low
doses of such drug, which hardly induce apoptosis.
In order to find the metabolic changes caused by the
low doses of edelfosine, Isodyn simulated the isotopo-
mer distribution using the available enzyme kinetic
information and the experimentally acquired
13Ci s o t o -
pomer distribution data. This approach allowed us to
obtain sets of fluxes in the modeled metabolic network,
which were consistent with the experimental distribu-
tion of mass isotopomers derived from labeled glucose
in the presence of edelfosine. The determination of the
metabolic conditions that promote apoptosis could be
an essential contribution to the therapy of cancer.
Results and Discussion
Glucose consumption and lactate production
The rates of glucose consumption normalized per cell
volume (for the convenience of comparison with the
other intracellular fluxes) were defined taking into
account the change of cell number and concentrations
of medium glucose and lactate as it is described in
“Methods”. These fluxes are summarized in Table 1.
These values calculated directly from experimental data
were used in the fitting of isotopic isomer distribution
described below.
Measured isotopomer distributions
Since the objective of this work was to register meta-
bolic changes that precede the development of apopto-
sis, very low doses of apoptosis inducing drug edelfosine
were used (0.5 and 1 μg×m L
-1)f o r
13C metabolite dis-
tribution experiments. After 48 hours of treatment, the
dose of 0.5 μg×m L
-1 induced less than 1% of apoptosis
whereas the dose of 1 μg×m L
-1 induced between 4 to
5% of apoptosis (measured as subG1 population with
respect total number of cells). Incubation with
[1,2-
13C2]-glucose as a tracer resulted in a specific isoto-
pomer (
13C isotopic isomer) distributions in metabolites,
which was measured by GC/MS techniques in medium
lactate and ribose-5-phosphate (r5p) derived from intra-
cellular RNA. The applied technique determined the
fractions of different mass isotopomers: m0 (without
any
13C labels), m1 (with one
13C label), m2 (with two
Table 1 The metabolic fluxes of glucose consumption
(JGlc) and lactate production (Jlac).
JGlc (mM/min) JLac (mM/min)
Con 0.09 0.1225
e0.5 0.1196 0.1565
e1 0.1359 0.1279
The fluxes are computed for the cells incubated in control conditions (con)
and with 0.5 μg×m L
-1 or 1 μg×m L
-1 of edelfosine (e0.5 and e1
respectively).
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sine-treated cells are shown in Table 2.
Simulation of measured isotopomer distributions
The distribution of isotopomer fractions of a metabolite
contains information about the fluxes through the meta-
bolic pathways of its formation. Roughly, when
[1,2-
13C2]-glucose is metabolized, anaerobic glycolysis
produces mainly m2 lactate, whereas passage of labeled
g l u c o s et h r o u g ht h eT C Ac y c l e( i n c l u d i n ga n a p l e r o t i c
pyruvate carboxylation, pyr®oaa) or the oxidative and
non oxidative branches of the pentose phosphate path-
way results in m1 and m3 lactate. Thus, the fractions of
m1 and m3 with respect to m2 characterize the contri-
bution of the TCA cycle and pentose phosphate path-
way. The simulation and fitting the measured
isotopomer distribution allows the determination of a
set of metabolic fluxes, which correspond to the mea-
sured isotopomer distribution. The details of such deter-
mination are described in method section and in [8-10]
and Additional file 1.
The results of data fitting by Isodyn are also presented
in Table 2. The quality of fit is characterized by c
2,t h e
sum of squares of differences between experimental and
simulated data normalized by the standard deviations of
experimental data. The ribose used for the analysis was
extracted from cellular RNA. Thus, the isotopomer dis-
tribution in ribose contains information on both the
label isotopomer distribution of the de novo synthesized
nucleotides and also on the fraction of initial non-
labeled nucleotides that were reused. The program cal-
culates this initial fraction with respect to the one
synthesized de novo during the treatment (as described
in Additional file 1); it is referred in the tables as “dilu-
tion” and characterized RNA synthesis de novo. Accord-
ing to the data of Table 2, in edelfosine-treated cells
dilution decreased, which indicates that a greater frac-
tion of RNA was synthesized de novo.
Analysis of metabolic flux profiles
Table 3 show the fluxes corresponding to the best fit
shown in Table 2 and indicates the fluxes for which the
difference between treated and non-treated cells are sta-
tistically significant. According to the table, to fit the
measured isotopomer distribution in cell population
where edelfosine induced ≤5% of apoptosis, glucose con-
sumption (via hk, hexokinase activity) must increase, the
TCA cycle (via pdh, pyruvate dehydrogenase activity)
must be activated and pentose phosphate pathways
must be inhibited with respect to the control.
Table 3 illustrates that a small change in the distribu-
tion of mass isotopomers shown in Table 2 could be a
consequence of large changes in metabolic fluxes. Speci-
fically, the flux through the TCA cycle (pdh, citrate
synthase, flux from citrate to malate) increases almost
three folds although the stimulation of apoptotic pro-
gram can be measured in only 4-5% of cells. These
fluxes normalized per respective glucose uptake are
increased also, although not so tremendously. Thus, the
low doses of edelfosine activate the whole central meta-
bolism and even more activate the TCA cycle. In fact, it
is not so simple to decide what value, normalized or not
normalized, characterizes the TCA cycle activation bet-
ter. Although glycolysis provides substrates for the TCA
cycle, it is known that activation of glycolysis is not
necessary coupled with the activation of the TCA cycle.
For instance, in muscle cells starting active contractions,
a hundred fold increase in glycolysis hardly activativates
TCA cycle [28]. Glycolysis has much more capacity for
activation, while the activation of the TCA cycle coupled
directly with mitochondrial bioenergetics requires much
more structural changes. If the TCA cycle is activated
Table 2 Isotopomer distribution in lactate secreted into the medium and RNA ribose
Lactate: control sd fit 0.5 μg/mL sd fit 1 μg/mL sd fit
m0 0.7900 0.003 0.7900 0.7860 0.001 0.7860 0.7910 0.003 0.7920
m1 0.0097 0.001 0.0096 0.0099 0.000 0.0099 0.0098 0.001 0.0098
m2 0.1990 0.003 0.1990 0.2030 0.001 0.2030 0.1980 0.003 0.1970
m3 0.0013 0.001 0.0013 0.0013 0.001 0.0013 0.0010 0.002 0.0011
Rib-5-P
m0 0.5480 0.011 0.5480 0.5570 0.003 0.5570 0.5790 0.011 0.5790
m1 0.2310 0.004 0.2310 0.2210 0.007 0.2250 0.2130 0.004 0.2110
m2 0.1490 0.005 0.1490 0.1410 0.003 0.1430 0.1340 0.005 0.1390
m3 0.0423 0.001 0.0420 0.0483 0.005 0.0449 0.0426 0.001 0.0418
m4 0.0299 0.001 0.0296 0.0325 0.002 0.0293 0.0312 0.001 0.0291
dilution: 0.3450 0.2080 0.2920
c 0.1760 4.7400 5.7500
The distribution was measured after 48 hours of incubation was assessed in Jurkat cells without drugs (control) or treated with either 0.5 μg×m L
-1 of edelfosine
that caused less than 1% of apoptosis (0-1%) or with 1.0 μg×m L
-1 of edelfosine that caused 4-5% of apoptotis (4-5%). Best fit obtained with Isodyn is depicted
in column “fit”. For Ribose, dilution (initial fraction with respect to the newly synthesized fraction during the treatment) is also shown.
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by mitochondria, this activation probably could have
negative consequences for cell survival.
Despite the changes in isotopomer distribution induced
by a low dose of edelfosine is small, c
2 criterion is suffi-
ciently sensitive to them. The program fits the data for
control with very small deviations (c
2 = 0.18). Howener,
if this “control” set of parameters is used to simulate the
data for treated cells, c
2 increases to 60, which indicates
that the model well accepted as a simulator of metabolic
fluxes in control cells becomes unacceptable for the edel-
fosine-treated cells. Subsequent fitting procedure
decreases c
2 to 5.75 (Table 2) just by increase of meta-
bolic fluxes through the TCA cycle and changes in the
pentose phosphate pathway as Table 3 indicates.
The activation of the TCA cycle, revealed for a low
dose of edelfosine, could be a reason for the activation
of apoptotic process when higher doses of drug are
applied. The main function of the TCA cycle in energy
metabolism is to produce substrates for mitochondrial
respiration. Therefore, the activation of TCA cycle
favors the reduction of electron transporters. This is a
factor that could switch the mitochondrial respiratory
chain to the state of damaging generation of reactive
oxygen species (ROS) [29], which is an important com-
ponent of apoptotic process. The low doses used for the
metabolomic studies did not increase ROS production,
although their metabolic effect was significant. The
increase of dose of edelfosine eventually produce signifi-
cant increase of ROS, as it is shown in Figure 1. This
Table 3 Simulated metabolic fluxes corresponding to the best fit presented in Table 2
flux Control Edelf: 0.5 μg/mL Edelf:1 μg/mL
hk*** 0.0901118 1 0.12 1 0.135 1
pfk 0.0968532 1.07481 0.120985 1.00821 0.135572 1.004237
fbpase 0.00716729 0.07954 1.46E-3 0.01219 0.0009715 0.007197
pep- > g3p 0.00694225 0.07704 0.00749499 0.06246 0.0025560 0.018933
g3p- > pep 0.186074 2.06492 0.246177 2.05148 0.271442 2.010681
pk 0.181224 2.01110 0.253755 2.11463 0.28068 2.079111
TCA- > pyr 2.23E-3 0.02470 0.0152166 0.12681 0.0118396 0.087701
lac- > 0.12219 1.35598 0.153661 1.28051 0.128901 0.954822
pdh*** 0.057984 0.64347 0.0815881 0.67990 0.140089 1.037696
pc 1.05E-3 0.01165 0.0185053 0.15421 0.0116895 0.086589
CitSyn** 0.0351159 0.38969 0.0547404 0.45617 0.120038 0.889170
cit- > mal** 0.0366362 0.40656 0.0549581 0.45798 0.120969 0.896067
PPP* 1.32E-4 1.47E-3 2.80E-6 2.33E-5 3.93E-6 2.91E-5
r5p- > 4.38E-4 0.00486 6.84E-4 0.00570 0.0005799 0.004296
cit- > glt 3.50E-3 0.03884 2.13E-3 0.01775 0.0014090 0.010437
- > cit 0.00549634 0.06099 2.35E-3 0.01959 0.0023398 0.017332
Transketolase:
xu5p- > s7p*** 0.00826654 0.09174 2.26E-7 1.88E-6 1.46E-6 1.08E-5
s7p- > xu5p 0.0084719 0.09402 4.24E-4 0.00353 0.0003579 0.002651
f6p- > xu5p 5.66E-4 0.00628 3.54E-5 0.00030 3.03E-5 0.000224
xu5p- > f6p*** 5.38E-4 0.00597 3.45E-9 2.87E-8 1.89E-8 1.40E-7
f6p- > s7p 0.00534401 0.05930 2.46E-4 0.00205 0.0001979 0.001466
s7p- > f6p 0.0052113 0.05783 4.49E-5 0.00037 3.08E-5 0.000228
xu5p < - > g3p*** 8.75E-4 9.71E-3 3.26E-8 2.71E-7 2.21E-7 1.64E-6
f6p < - > e4p 3.48E-4 0.00386 3.75E-6 3.12E-5 2.63E-6 1.95E-5
r5p < - > s7p 0.0800302 0.88812 2.94E-3 0.02453 0.0023626 0.017501
Transaldolase:
f6p- > s7p 1.54E-4 0.00171 2.57E-4 0.00214 0.0002003 0.001484
s7p- > f6p 2.48E-5 0.00028 2.25E-5 0.00019 4.54E-6 3.36E-5
f6p < - > g3p 2.64E-7 2.93E-6 1.09E-6 9.05E-6 2.51E-7 1.86E-6
s7p < - > e4p 0.0144573 0.16044 0.0053368 0.04447 0.0037384 0.027691
The fluxes were computed for cells incubated for 48 hours without drugs (control) or treated with either 0.5 μg×m L
-1 of edelfosine that caused less than 1% of
apoptosis (0-1%) or with 1.0 μg×m L
-1 of edelfosine that caused 4-5% of apoptotis (4-5%). Left column for each condition shows absolute value of the flux (in
mM × min
-1 in intracellular volume), right column shows the values normalized per respective glucose uptake (hk). The flux depicted as TCA- > pyr is a sum of
fluxes through pepck and malic enzyme, that resulted in the same isotopomer distribution and contribute to the
13C enrichment in lactate from the TCA cycle.
Arrows indicate the directions of fluxes; stars indicate the fluxes for which the absolute values (not normalized) are statistically different from control (***, p <
0.01; **, p < 0.05; *, p < 0.1).
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studies reported elsewhere [20,27], validates the conclu-
sion based on the isotopomer distribution data analysis.
Another important distinction in the revealed flux
profiles of control and edelfosine-treated Jurkat cells is
the difference in the fluxes of pentose phosphate path-
way. In control cells all pentose phosphate fluxes were
higher than those in edelfosine-treated cells (Table 3).
Moreover, the model predicted an increase in ribose
consumption for RNA synthesis in edelfosine-treated
cells, which led to a decrease in ribose 5-phosphate con-
centration, such that its synthesis became practically
unidirectional. Thus, newly synthesized ribose 5-phos-
phate was consumed for RNA synthesis to a greater
extent in edelfosine-treated cells than control (see flux
r5p, Table 3), in accordance with the value of
13C
dilution in r5p (see Table 2). In contrast, in control
cells, the newly synthesized ribose 5-phosphate is not
massively used for RNA synthesis, but reutilized in the
central energetic metabolism.
Conclusions
The simulation of changes in isotopomer distribution
induced by low doses of edelfosine revealed essential
activation of the TCA cycle (including anaplerosis).
Such direction of changes in metabolism could enhance
ROS production when the higher doses of drug are
applied. Indeed, when doses of edelfosine causing >5%
of apoptosis rate were used (from 1 to 2 μg×m L
-1)t h e
increase of ROS production becomes measurable
experimentally.
Another effect of the drug is the stimulation of RNA
synthesis. Both effects of the drug are consistent: the
increase of the TCA cycle fluxes are aimed in the
increase of ATP energy production necessary for biosyn-
thetic processes induced by such stress factor as
edelfosine.
Methods
Structure of program and algorithms for isotopomer
distribution analysis
The computer program “Isodyn”, which we developed in
C++, represents a simulation environment for the
dynamics of metabolite labeling by
13C isotopes in meta-
bolic reactions of living cells. For such simulations it
uses a classical kinetic model of metabolic pathways
linked with a module that computes the distribution of
13C isotopic isomers of metabolites. For the case of
metabolic steady state it uses following algorithm for
the simulation of dynamics of isotopomer distribution in
metabolites.
1. To simulate reaching steady state in the kinetic
model for total metabolite concentrations and fluxes
for a given set of parameters.
2. To decompose the combined fluxes of kinetic
model to the isotope-exchange fluxes, which differ-
ently affect isotopomer distribution.
3. To simulate the distribution of isotopomers using
the total metabolite concentrations and decomposed
fluxes obtained in steps 1 and 2.
Each simulation, performed through the steps 1-3,
gives the distribution of isotopomers. The computed
distribution is compared with the measured one using
c
2 criterion (see below) and a procedure of optimization
is applied, which changes parameters and performs cal-
culations each time passing through steps 1-3 with the
objective to decrease c
2. The steps 1-3 and the proce-
dure of optimization are described next.
Figure 1 Increase in DCF fluorescence in edefosine-treated
Jurkat cells. The DCF fluorescence as a result of ROS production
was measured in a fluorescence microplate reader (top panel) and
by fluorescence microscopy (left images, bottom two panels). Also
shown are the phase-contrast images superimposed with the
fluorescence images of the Jurkat cells (right images, bottom two
panels).
Selivanov et al. BMC Systems Biology 2010, 4:135
http://www.biomedcentral.com/1752-0509/4/135
Page 5 of 11Step 1
The classical kinetic model is represented by a system of
ordinary differential equations (ODE) simulating the
evolution of concentrations of metabolites:
dd t   cN v c , p / = () (1)
here c ={ c 1,c 2, ..., cm} is the vector of m metabolite
concentrations described by the model. The metabolites
considered in this particular case are presented in Fig-
ure 2. This scheme reflects the simplifications accepted
for the model, in particular, pentoses represented by r5p
and xu5p, which are in fast equilibrium. Oxidative branch
of pentose phosphate pathway is represented by one
reaction converting g6p into pentose phosphates. One
lumped reaction connects citrate with malate, g3p goes
directly to pep. We described in detail the most impor-
tant reactions where carbon skeleton changes and label is
redistributed, and combined the reactions which either
do not change the carbon skeleton or only release CO2.
N ={ n ij}, i = 1, ..., m, j = 1, ..., k is stoichiometric
matrix for m metabolites and k reactions and v(c,p) =
{v1(c,p), v2(c,p), ..., vk(c,p)}, is the vector of k reaction
rates (metabolic fluxes), which are functions of concen-
trations and parameters such as Vmax. Concentrations
vary with time in accordance with (1), and parameters
are constant in each simulation, but they are unknown
and could be found by fitting the experimental data.
The rates for the most of enzymatic reactions are
described by Michaelis’ equation, although the reactions
performing splitting/reformation of carbon skeleton of
substrate molecule are considered in more detail taking
into account the known elementary steps of reaction
mechanism, as exemplified below for aldolase reaction.
Matrix N is organized in such a way that production
(input) and consumption (output) for the metabolites
correspond to the arrows shown in Figure 2. Additional
file 1 describes the whole set of differential equations of
the model, which included the reactions of glycolysis,
the TCA cycle, anaplerotic reactions, pentose phosphate
pathway (PPP), exchange with extracellular glucose, lac-
tate, and glutamate, and also the biosynthetic fluxes to
nucleic acids and fatty acids. By solving these equations
numerically, the program computes evolution of total
metabolite concentrations and metabolic fluxes for a
given set of parameters (Vmax, Km, rate constants).
Step 2
According to (1) differential equation for the concentra-
tion of a metabolite s (cs) is:
dc dt n v c p ss j j /, = () Σ (2)
The reactions j, which change concentrations cs,
change also the concentrations of isotopomers xs ={ x s1,
xs2, ... ,xsI}. However, the net reaction rate vi accounted
for kinetic model (1) could be composed of several iso-
tope exchange processes, which differently affect isoto-
pomer distribution and have to be accounted separately.
Below we describe an example of such decomposition
for aldolase reaction. Thus, reactions vi should be
decomposed to several reactions ui: vi ® ui1,u i2 .... This
decomposition depends on reaction mechanism and is
specific for each particular reaction. For instance, if a
reaction does not produce any change in carbon skele-
ton of substrates, the decomposition implies only that
the rates of transformation of substrate (uf) into product
and reverse transformation of product into substrate
(ur) must be calculated separately. The change of isoto-
pic composition of reactants depends not only on net
reaction rate (vi = uf - ur) ,b u to nt h ef o r w a r da n d
reverse rates taken separately. If a reaction performs
splitting/reformation of carbon skeleton of substrate
Figure 2 Schematic representation of the main fluxes
simulated in the model to study the edelfosine-induced
apoptosis in the Jurkat cell line. The description is presented in
“Methods” and, in more detail, in Additional file 1.
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from forward and reverse reaction rates, could take
place. Specifically, for aldolase reaction: fbp ↔ g3p +
dhap, which proceeds through several elementary steps:
1. e + fbp ↔ e-fbp
2. e-fbp ↔ e-dhap + g3p
3. e-dhap ↔ e + dhap,
the fluxes through the whole reaction cycle (reactions
1-3) in the forward and reverse directions (uf, ur)a n d
also the exchange flux of a half of fbp molecule with
g3p (fbp ↔ g3p, steps 1 and 2 without entering to step
3, ue) should be evaluated. The latter does not change
the total metabolite concentrations but it characterizes
the interchange of first three atoms of fbp with g3p
pool. uf and ur change also total concentrations, their
values indicate the transition of last three atoms of f6p
to and from dhap. The algorithms for the calculations
of such isotope exchange fluxes for given parameters
and metabolite concentrations are described elsewhere
(Selivanov et al, 2005).
For transaldolase reaction, f6p+e4p ↔ s7p+g3p, in
addition to the forward and reverse fluxes through the
whole reaction cycle two additional isotope exchange
fluxes should be evaluated: f6p ↔ g3p and s7p ↔ e4p.
For transketolase reactions (x5p+r5p ↔ s7p+g3p, f6p
+g3p ↔ x5p+e4p, f6p+r5p ↔ s7p+e4p) in addition to
the six forward and reverse fluxes through these three
reaction cycles the isotope exchanges x5p ↔ g3p, f6p ↔
e4p and s7p ↔ r5p should be evaluated.
All the isotope exchange fluxes necessary for the cal-
culation of isotopomer dynamics could be evaluated if
the total metabolite concentrations are known after the
execution of kinetic model. When the kinetic simulation
is done, Isodyn calculates the necessary isotope
exchange fluxes in one step, as explained in more details
in (Selivanov et al, 2005) and Additional file 1.
Step 3
When all the preparations are done (i.e. total metabolite
concentrations and necessary fluxes are computed), the
system of equations of type (3) for all isotopomers could
be solved. Isodyn calls a module, which performs the
computation of isotopomer dynamics.
The differential equations for isotopomers of each of
m considered metabolites after the decomposition of
fluxes could be presented in the form similar to (2):
dx dt n w u si j h sj j jh /, = () () ΣΣ c,p c,x (3)
here wj is individual reaction rate that changes the
concentration of isotopomer xsj, which depends on the
decomposition ujh of rate vj, vector of total concentra-
tions c and isotopomer concentrations x.
Equation (3) describes the evolution of concentration
of isotopomer i of substance s. To simulate the isotopo-
mers distribution in metabolites, which are described by
kinetic model (1), the equations of type (3) must be
written for all the isotopomers of considered metabo-
lites. This procedure is automated in our software.
To calculate the derivatives of isotopomers, the func-
tions, which are specific for each reaction type, simulate
the reaction mechanism in order to define the products
for each isotopomer-substrate and also calculate the
reaction rate for each given isotopomer transformation.
The simulation of reaction mechanism is based on
operations with binary numbers. Since only two carbon
isotopes are considered, any combination of carbons in
the skeleton of a molecule could be reflected by a
respective binary number, where “1” states for
13Ca n d
“0” states for
12C. In this way all hexose isotopomers
could be represented by numbers from 000000 (decimal
0) to 111111 (binary equivalent of decimal 63), triose
isotopomers range from 000 to 111 (decimal 7), etc.
When Isodyn simulates reactions for isotopomers it
splits/recombines the binary representation of isotopo-
mers in the same way as enzymes split and reform
molecules. For instance since aldolase splits hexose (fbp)
into two trioses, the respective Isodyn function splits
binary numbers of fbp representatives, taking them one
by one subsequently, e.g. when it takes “010101”,i t
splits it to “010” and “101”. The number 010101 (binary
equivalent of decimal 21) indicates the position of the
value of this isotopomer concentration (C010101 with
binary index or C21 with decimal index) in the array of
concentrations of fbp isotopomers. Knowing thus the
position (and hence the concentration) of given isotopo-
mer the algorithm calculates the reaction rate for a each
isotopomer in a given reaction based on the total reac-
tion rate (u
ald
t) and total concentration (C
fbp
t)k n o w n
from the kinetic model simulation:
uu * C / C
ald ald
t2 1
fbp
t 21 = (4)
this rate is subtracted from the derivative of 21
st isoto-
pomer of fbp and added to the derivatives of trioses
“010” (decimal 2) and “101” (decimal 5). The arrays of
derivatives are organized in the same way as those for
concentrations.
The same isotopomers could participate in various
reactions. Isodyn simulates all of them adding the reac-
tion rates (with correct sign) to the respective deriva-
tives. The functions performing such simulations are
described in Additional file 1. They constitute a library,
which can be used selectively.
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on and could be solved simultaneously with (1). How-
ever, if the dynamics of isotopomer distribution is simu-
lated in the conditions of metabolic steady state, the
procedure of numerical solution could be simplified so
that the general kinetic equations (1) could be solved
separately from the solution for isotopomers (3). This
case is presented here as the steps 1-3.
Here is a small example of application of above metho-
dology, where we organize the calculation of derivatives
for all the isotopomers of system consisting of substrate
and product of pdh reaction with constant pyruvate
input: v0 ® pyr ® accoa ®. Let it is at metabolic steady
state with initial isotopomer distribution for pyruvate
(C000,C 001,C 010,C 011,C 100,C 101,C 110,C 111)a n da c c o a
(C00,C 01,C 10,C 11). Let v0 is constant input of unifor-
mely labeled pyruvate (111). In this system at steady
state all rates are v0, and let the computed total concen-
trations for some given set of parameters are Cpyr and
Caccoa. Simulating this process Isodyn calls three func-
tions that simulate respectively three reactions of the
system. First function simulates constant input, it simply
gives value v0 to the derivative of uniformely labeled
pyruvate, not touching other derivatives (D111 =v 0).
Then, the function, which simulates pdh takes the arrays
for pyr and accoa, calculates what accoa isotopomer is
produced from each substrate simulating decarboxyla-
tion by removing the first digit from binary representa-
tion of pyr, calculates the rates for each isotopomer
transition, and adds this rate to the value of respective
derivative as it is demonstrated in Table 4.
Then Isodyn calls a function that simulates efflux of
accoa as it is demonstrated in Table 5.
After the simulation in such a way of all the reactions
of considered pathway, the whole array of derivatives (3)
for all isotopomers at a given time point is formed. The
function that calculates derivatives as described above
could be called by any ODE solver, which solves the
ODE system thus constructed. Isodyn implements sev-
eral methods for ODE solving provided for C++ by
Press et al [30], including fourth-order Runge-Kutta,
Bulirsch-Stoer and Rosenbrock method for stiff systems.
Also is implemented implicit Runge-Kutta 5
th order
method for stiff systems (Radau5), described in [31] and
backward differentiation formulas as their implemented
in the solver DASSL [32] written in Fortran but linked
with the C++ code of Isodyn. The implementation of
various methods allows to find the fastest solution for a
given problem. In the problem considered here the
combination of DASSL for kinetic model with Runge-
Kutta method as it is implemented in [30] for isotopo-
mer distribution provided the fastest way to obtain
solution.
The fact that solving the equations of kinetic model is
followed by solving the system for isotopomers gives a
way of checking solutions. Isodyn checks if the sum of
isotopomers obtained after solving large isotopomer sys-
tem is the same as total concentrations of metabolites
obtained by kinetic model. The large isotopomer system
could easily became stiff so that the employed method
of solution does not provide necessary accuracy. In this
case the program indicates the inaccuracy of solution.
Optimization
Simulation with an initial set of kinetic parameters gives
a set of fluxes and corresponding isotopomer distribu-
tion, which could be compared with the measured dis-
tribution. Mass isotopomers of lactate and ribose were
measured; to compare them with model prediction, the
sums corresponding to respective measured mass isoto-
pomers were calculated and the fractions with respect
to the total amount were found. The difference between
experimental data and the prediction was characterized
by normalized square deviations (c
2=Σi((f
e
i-f
t
i)/s
e
i)
2),
where f
e
i is experimental mass isotopomer fraction, f
t
i is
the predicted one, s
e
i is experimental standard devia-
tion. The objective was to find the set of parameters
(Vmax for simple reactions described by Michaelis’
equation with fixed Km, and rate constants for elemen-
tary steps of more complex reactions like transketoliase
Table 4 The algorithm for the automated calculation of
reaction rates (column “rate”) and time derivatives for all
the isotopomers (shown in left column) of pyruvate
(dpyr /dt) and accoa (daccoa /dt) exemplified for pdh
reaction (pyr ® accoa).
reaction rate dpyr/dt daccoa/dt
000 ® 00 u000=v 0C000/Cpyr D000=- u 000 D00=u 000
001 ® 01 u001=v 0C001/Cpyr D001=- u 001 D01=u 001
010 ® 10 u010=v 0C010/Cpyr D010=- u 010 D10=u 010
011 ® 11 u011=v 0C011/Cpyr D011=- u 011 D11=u 011
100 ® 00 u100=v 0C100/Cpyr D100=- u 100 D00=u 000+u100
101 ® 01 u101=v 0C101/Cpyr D101=- u 101 D01=u 101+u001
110 ® 10 u110=v 0C110/Cpyr D110=- u 110 D10=u 110+u010
111 ® 11 u111=v 0C111/Cpyr D111=v 0-u111 D11=u 111+u011
Table 5 The algorithm for the automated calculation of
reaction rates (column “rate”) and time derivatives for
all the isotopomers (shown in left column) of accoa
(daccoa /dt) exemplified for the reaction of efflux of
accoa (accoa ®)
reaction rate daccoa /dt
00 ® u00=v 0C00/Caccoa D00=u 000+u100-u00
01 ® u01=v 0C01/Caccoa D01=u 101+u001-u01
10 ® u10=v 0C10/Caccoa D10=u 110+u010-u10
11 ® u11=v 0C11/Caccoa D11=u 111+u011-u11
The pdh reaction (pyr → accoa) shown in Table 4 was already taken into
account.
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Page 8 of 11and transaldolase, described elsewhere [9], in total 29
parameters), which minimize c
2.T ot h i se n dw es u b s e -
quently used modified Simulated Annealing algorithm
[33] and genetic algorithm. Random change of para-
meter values in Simulated Annealing we combined with
Powell’s method of coordinate descent [30], modifying
each parameter in the direction that provides decrease
of c
2. After each stochastic perturbation of parameters
and descent to a local minimum of c
2, Isodyn saved the
set of parameters and respective fluxes corresponding to
the local minimum. These sets were used as an initial
population for genetic algorithm. It performed crossover
of these sets, “mutations” of randomly selected para-
meters and selection of obtained sets using the same cri-
terion of c
2. After the finding the global minimum of c
2
a range of fluxes corresponding to a specific level of
confidence of c
2, was taken as a confidence interval cor-
responding to the chosen level of confidence [30].
Experimental methods
Cell culture conditions
Jurkat (acute T cell leukaemia), obtained form the
American Type Culture Collection, were grown in
RPMI 1640 culture medium (Sigma-Aldrich Co, St
Louis, MO) supplemented with 10% heat-inactivated
FCS (PAA Laboratories, Pasching, Austria), 2 mM
L-glutamine, 100 U × mL
-1 of penicillin and 100 μg×
mL
-1 of streptomycin (Invitrogen, Paisley, UK) at 37°C
in a humidified atmosphere of 5% CO2.A tt h et i m eo f
treatment with edelfosine for isotopomeric distribution
analysis, cells (250000 cells × mL
-1) were incubated in
75cm
2 Petri dishes in the RPMI 1640 medium, and with
10 mmol × L
-1 of [1,2-
13C2]-glucose (Sigma-Aldrich Co,
St Louis, MO) at 50% isotope enrichment for 48 hours.
At the end of the incubations, cells were centrifuged
( 1 , 5 0 0r p mf o r5m i n u t e s )a n dm e d i u mw a sc o l l e c t e d
for glucose and lactate analysis, whereas cell pellets
were frozen for RNA ribose analysis. Cells were counted
with a haemocytometer, and edelfosine-induced apopto-
sis was assessed by flow cytometry using a fluorescence-
activated cell sorter (FACS), as the percentage of cells in
the sub-G0 region (hypodiploidy) in cell cycle analysis.
Glucose and lactate concentration
From culture medium, glucose and lactate concentration
were determined as previously described [34,35] using a
Cobas Mira Plus chemistry analyzer (HORIBA ABX,
Montpellier, France) at the beginning and at the end of
the treatments.
The calculation of fluxes of glucose consumption and
lactate production normalized per intracellular volume
The glucose (Cg) consumption rate (v) normalized per
number of cells can be defined as follows. Glucose con-
sumption rate for the given number of cells nt is
dC
dt
vn
g
t =× (5)
Assuming exponential cell growth nt could be
expressed as:
nne t
kt =×
×
0 (6)
Separation of variables in (5) with substitution (6)
gives:
dC
vn
k
ed kt g
kt =
×
××
× 0 () (7)
Integration of (7) gives
Δ
Δ
C
v
k
nn v
Ck
nn
gt
g
t
=− =
×
−
() 0
0
and (8)
k could be defined from (6):
k
nn
t
t =
ln( / ) 0 , and substitution in (8) gives:
v
Cn n
nn t
gt
t
=
×
−×
Δ ln( / )
()
0
0
(9)
During the 48 hours of incubation without edelfosine
(control) the number of cells in average increased from
0.25 × 10
6 cells × mL
-1 to 0.36 × 10
6 cells × mL
-1.G l u -
cose concentration decreased in average from 8.66 mM
to 4.76 mM.
v
mol
cells
=
×
×− ×
=
39 03 6 02 5
10 0 36 0 25 2880
0 0045 6
.( . / . )
(. . ) m i n
.
 ln  mol
cells 10
6 ×min (10)
This consumption of glucose induces changes in intra-
cellular concentrations of metabolites. To compare this
flux with intracellular metabolic fluxes the units were
changed to mM/min in the intracellular volume by
dividing the above value of v to the volume of 10
6 cells,
which was 0.05 mL:
v
mol
cells
mM
=
×
= 0 0045
10
00 9 6 .
min
.
min

(11)
This value characterizes the change of intracellular
concentration per minute and all the fluxes were
expressed in the same units.
Lactate isotopomer distribution
Lactate from the cell culture medium was extracted by
ethyl acetate after acidification with HCl. Lactate was
derivatized to its propylamideheptafluorobutyric form
and the m/z 328 (carbons 1-3 of lactate, chemical ioni-
zation) was monitored as described [36].
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Page 9 of 11RNA Ribose isotopomer distribution
RNA ribose was isolated by acid hydrolysis of cellular
RNA after Trizol (Invitrogen) purification of cell
extracts. Ribose isolated from RNA was derivatized to
its aldonitrile acetate form using hydroxyl-amine in pyri-
dine and acetic anhydride. We monitored the ion cluster
around the m/z 256 (carbons 1-5 of ribose, chemical
ionization) to find the molar enrichment and distribu-
tion of
13C labels in ribose
43.
Gas Chromatography/Mass Spectrometry
Mass spectral data were obtained on the HP5973 mass
selective detector connected to an HP6890 gas chroma-
tograph. The settings are as follows: GC inlet 230°C,
transfer line 280°C, MS source 230°C, MS quad 150°C.
An HP-5 capillary column (30 m length, 250 μmd i a -
meter, 0.25 μm film thickness) was used for analysis of
ribose and lactate.
In vitro experiments were carried out using duplicate
cultures each time for each treatment regimen. Mass
spectral analyses were carried out by three independent
automated injections of 1 μl of each sample and were
accepted only if the standard sample deviation was less
than 1% of the normalized peak intensity.
ROS production
ROS production was monitored using the fluorescente
probe 2’,7’-dichlordihydrofluorescein diacetate
(H2DCFDA) (Invitrogen, Carlsbad, CA). Jurkat cells
(150,000 cells/well) were grown in RPMI 1640 medium
(as described above) in 6-well culture plates. Prior to
Edelfosine treatment, cells were harvested by centrifuga-
tion and preloaded with 10 μMH 2DCFDA in PBS for
30 min at 37°C, followed by wash in PBS to remove
unloaded probe, addition of fresh medium containing 0-
2 μg×m L
-1 edelfosine, and incubation at 37°C/5% CO2
for 48 hr. After treatment, cells were harvested, washed
in PBS twice, and resuspended in PBS before DCF fluor-
escence was read with excitation and emission wave-
lengths at 495 nm and 527 nm, respectively. All
fuorescence readings were normalizad to cell counts.
The same treatment was also performed for cells grown
in cover slips and DCF fluorescence examined using a
BX51 fluorescence microscope (Olympus, Melvilla, NY).
Additional material
Additional file 1: Supplementary materials. PDF containing
supplemental figures and other information.
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